123
Participants
Start Date
March 27, 2015
Primary Completion Date
September 1, 2017
Study Completion Date
March 2, 2023
Clobetasol Propionate
Given topically
Pharmacological Study
Correlative studies
Quality-of-Life Assessment
Ancillary studies
Regorafenib
Given PO
Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse
Roswell Park Cancer Institute, Buffalo
Geisinger Medical Center, Danville
Wake Forest University Health Sciences, Winston-Salem
Wellmont Medical Associates Oncology and Hematology-Kingsport, Kingsport
Ohio State University Comprehensive Cancer Center, Columbus
Toledo Clinic Cancer Centers-Toledo, Toledo
Northern Indiana Cancer Research Consortium, South Bend
Siouxland Regional Cancer Center, Sioux City
Saint Vincent Hospital Cancer Center Green Bay, Green Bay
Marshfield Clinic, Marshfield
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park
Mayo Clinic, Rochester
Illinois CancerCare-Peoria, Peoria
Washington University School of Medicine, St Louis
Missouri Valley Cancer Consortium, Omaha
University of Nebraska Medical Center, Omaha
Mayo Clinic Hospital, Phoenix
Mayo Clinic in Arizona, Scottsdale
USC / Norris Comprehensive Cancer Center, Los Angeles
University of Washington Medical Center, Seattle
Dana-Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH
Academic and Community Cancer Research United
OTHER